By Editor , 30 September 2026
Lilly's Retatrutide Cuts Weight 20.8%, A1C 1.6% in Phase 3 Trial

Indianapolis – September 30, 2026 -- Eli Lilly and Company (NYSE: LLY) reported that its investigational triple hormone receptor agonist retatrutide produced an average weight loss of 49.6 lbs (20.8%) over 80 weeks at the 12 mg dose in patients with type 2 diabetes and obesity, with more than half of participants no longer meeting BMI criteria for obesity. The Phase 3 TRIUMPH-2 results were presented at the 62nd Annual Meeting of the European Association for the Study of Diabetes in Milan and simultaneously published in The Lancet.

By Editor , 29 September 2026

Kista, Sweden – September 29, 2026 -- Sivers Semiconductors AB has called an Extraordinary General Meeting for 22 October 2026 to replace auditor Deloitte AB with Ernst & Young AB, a move tied to the company's plan for a dual listing on U.S. capital markets expected in the first half of 2027.

By Editor , 29 September 2026
Lilly's Zepbound 15 mg Outpaces Wegovy HD by 4.5% in New Weight-Loss Analysis

Indianapolis – September 29, 2026 -- Eli Lilly and Company said a new indirect treatment comparison shows Zepbound (tirzepatide) 15 mg produced 4.5% greater body-weight loss than Novo Nordisk's Wegovy HD (semaglutide 7.2 mg) in adults with obesity, intensifying the competitive battle in the obesity-drug market. The 10 mg dose of Zepbound delivered 3.2% greater weight reduction than Wegovy HD, according to data presented at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan.

By Editor , 29 September 2026
Ozempic Dose Escalation Cuts Cardiovascular Risk 6% Versus Mounjaro Switch

Plainsboro, N.J. – – September 29, 2026 -- Novo Nordisk reported that adults with type 2 diabetes who escalated their semaglutide dose to 2 mg showed a statistically significant 6% lower risk of major adverse cardiovascular events (MACE) compared with patients who switched to tirzepatide, according to real-world data presented at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026 in Milan.

By Editor , 29 September 2026
Amcor Names Tom Long Chairman as Liebelt Retires After 13 Years

Zurich – September 29, 2026 -- Amcor (NYSE: AMCR, ASX: AMC) confirmed that Graeme Liebelt will step down as Chairman after nearly 13 years, with the Board electing Tom Long as his successor effective at the company's Nov. 11, 2026 annual meeting.

By Editor , 29 September 2026

Taipei – – September 29, 2026 -- ORing Industrial Networking, a Taiwan-based industrial networking specialist with 20 years of market experience, showcased its next-generation IRoN railway Ethernet switch portfolio at InnoTrans 2026.

By Editor , 29 September 2026

Espoo – September 29, 2026 -- Valmet Oyj's Board of Directors has confirmed that the second instalment of its 2025 dividend, EUR 0.67 per share, will be paid on October 7, 2026.

Shareholders on record October 1 qualify for payout

The dividend will go to shareholders registered in Valmet's shareholders' register held by Euroclear Finland Oy on the record date of October 1, 2026.